Article Details
Retrieved on: 2021-01-04 11:03:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Viela Bio's Uplizna and Roche's Enspryng became the first treatments for patients with NMOSD, a disease in which the immune system attacks the optic ...
Article found on: www.fiercebiotech.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here